Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
D6RGH6

UPID:
MCIN_HUMAN

ALTERNATIVE NAMES:
Multiciliate differentiation and DNA synthesis-associated cell cycle protein; Protein Idas

ALTERNATIVE UPACC:
D6RGH6; C9JGY3; D6R920; F8KGQ8

BACKGROUND:
The protein Multicilin, also referred to as Protein Idas, is crucial for the differentiation of multiciliate cells. It functions within a multiprotein complex, including E2F4 and E2F5, to activate genes necessary for centriole creation and the deuterosome-mediated acentriolar pathway. Its role extends to facilitating cell cycle exit and modulating GMNN's interaction with CDT1.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Multicilin could open doors to potential therapeutic strategies for combating primary ciliary dyskinesia and related syndromes, offering hope for treatments that address the underlying genetic causes of these diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.